Peptides, pharmaceutical compositions containing the peptides and a process for the preparation of the peptides

Description

[0001] This invention relates to certain peptides which may be used in desensitisation therapy, and to pharmaceutical compositions containing them.

[0002] It is known that allergic reactions in allergic humans are largely caused by the release of histamine from mast cells. This release is taken to be caused by the cross-linking of IgE antibodies attached to mast cells by allergen, which cross-linking is believed to distort the antibodies thereby bringing basic portions of the antibodies into proximity with the cell surface, which in turn causes release of histamine from the cell. It is also known that this histamine release from mast cells can be minimized by the use of antificial liberators, such as melittin, ACTH and fragments thereof (D.R. Stanworth, "Immediate Hypersensitivity", Chapter 8, North Holland Publishing Company, London, 1973, and B. Jasam and D.R. Stanworth Int. Arch. Allergy 45,74-81 (1973)).

[0003] In Belgian Patent No. 840193, one method for treating allergies is proposed. This is the use of a short amino acid sequence from the Fc portion of IgE to block IgE receptor sites on mast cells. In this way it is proposed that the allergen caused IgE cross-linking reaction, leading to histamine reiease from the mast cell to which the IgE is bound, maybe prevented or inhibited, as IgE molecules will be blocked from binding to mast cells by the presence on the mast cells of the said short amino acid sequences.

[0004] To put the disclosure of this Belgian Patent into perspective, it should be noted that although in our hands some success was obtained in confirming some aspects of the proposed system (D.R. Stanworth et al, Int. Arch Allergy appl. Immuno 56:409-415 (1978)) with the preferred penta peptide, other workers generally accepted as among the world's leading experts in the field were unable to demonstrate any of the claimed activity with the preferred penta peptide (Bennich, Ragnarsson, Johansson, K. Ishizaha, T. Ishizaka, Levy and Lichtenstein, Int. Archs Allergy appl. Immuno 53:459-468 (1977)).

[0005] A class of peptides has now been discovered which can be used in the desensitisation therapy of allergic humans. In complete contrast these peptides act by releasing histamine from mast cells, not by inhibiting or preventing such histamine release as alleged for the peptides disclosed in the said Belgian Patent.

[0006] Accordingly the present invention provides a peptide or a salt thereof, characterised by containing 6 to 12 naturally occuring amino acid residues in a sequence-[-R₁-R₂-R₃-], wherein, R₁ consists of a residue of a basic amino acid, optionally linked to one or more residue of a neutral non-hydrophobic amino acid and/or to one or more further residue of a basic amino acid; R₂ consists of one or more residue of a neutral non-hydrophobic amino acid; and R₃ consists of a residue of a hydrophobic amino acid, optionally linked to one or more residue of a neutral non-hydrophobic amino acid and/or to one or more further residue of a hydrophobic amino acid; the said basic amino acid residues are selected from arginyl, lysyl and ornithyl; the said neutral non-hydrophobic amino acid residues are selected from glycyl, alanyl, seryl and threonyl; and the said hydrophobic amino acid residues are selected from phenylalanyl, valyl and leucyl; said peptide having the formula (I):

wherein the sequence [-R₁-R2-R₃-] is as defined and; X is hydrogen, or a N-protecting group; Y is hydroxy, or a C-terminal protecting group; and R is an optionally present group, capable of confering on a peptide resistance to enzyme breakdown.

[0007] Unless otherwise stated, the amino acids referred to hereafter are in the L-configuration.

[0008] When R is present, it is a group capable of confering on a peptide resistance to enzyme breakdown. Examples of suitable groups R are given in J. Rudinger, "The Design of Peptide Hormone Analogues", Chapter 9 in Drug Design, Volume (II) edited by E. J. Ariëns, Academic Press, New York and London, 1971.

[0009] Thus suitable examples of R, when present, include prolyl, hydroxyprolyl, the D- form of a common amino acid residue or an amino acid residue with omission of the terminal amino group.

[0010] Particularly suitable examples of R₁ include Lys-Thr-Lys and Arg-Lys-Thr-Lys. Normally R₁ will consist of 1 to 5 amino acid residues, suitably 3 to 5 residues. R₁ will often contain at least two basic amino acid residues and at least one neutral non-hydrophobic amino acid residue.

[0011] A particularly suitable example of R₂ is Gly-Ser-Gly. Preferably R₂ consists of 1 to 5 amino acid residues, for example 3 amino acid residues.

[0012] Particularly suitable examples of R₃ include Phe-Phe and Phe-Phe-Val-Phe. Preferably R₃ consists of 1 to 4 amino acid residues, for example 2 or 4 residues.

[0013] X is hydrogen or a N-protecting group. Suitable examples of N-protecting groups X include those conventionally known for this use in peptide chemistry. Examples of such groups include carboxylic acid groups such as acetyl, chloroacetyl, trifluoroacetyl, butyryl, benzoyl, phenylacetyl, pyridine-carbonyl; or an acid group derived from carbonic acid such as ethoxycarbonyl, benzyloxycarbonyl, t-butyloxycarbonyl, biphenylisopropoxycarbonyl, p-methoxy-benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, p-phenylazobenzyloxycarbonyl, p-(p'-methoxyphenylazo)-benzyloxycarbonyl, t-amyloxycarbonyl; or an acid group derived from a sulphonic or p-toluene-sulphonic acid; or other groups such as benzyl, trityl, formyl, phthaloyl, o-nitrophenylsulphenyl, benzylidene or nitro. Preferred N-protecting groups X include t-butyloxycarbonyl or benzyloxycarbonyl.

[0014] Suitable C- terminal protecting groups Y include ester residues, for example residues of C_1-6 alkyl esters such as methoxy, ethoxy and t-butoxy, benzyloxy, p-nitrobenzyloxy, p-methoxybenzyloxy; residues of trimethylsilyl esters; and residues of amides, substituted amides (e.g. amides substituted by one or two C_1-6 alkyl groups, or by a C_1-6 acyl group), and hydrazino residues. Preferred groups Y include hydroxyl and methoxy.

[0015] The peptides of the invention have 6 to 12 amino acid residues in the ⁅R₁-R₂-R₃⁆ sequence. Preferably they have 8 to 10 amino acid residues in this sequence.

[0016] One particularly suitable group of peptides is of formula (II):

wherein X, Y and R are as defined; c and e are lysyl, arginyl or ornithyl; d is threonyl or seryl; b is an optionally present arginyl; lysyl or ornithyl; f and h are glycyl or alanyl; g is seryl or threonyl; i and j are phenylalanyl, valyl or leucyl; and k and I are optionally present phenylalanyl, valyl or leucyl; and salts thereof.

[0017] Preferably in formula (II) X is hydrogen and Y is hydroxyl, -NH₂ or C_1-4 alkoxy such as methoxy, and, when R is present, it is prolyl or hydroxyprolyl.

[0018] Examples of peptides within the scope of the invention are:

Lys Thr Lys Gly Ser Gly Phe Phe-^y1

Arg Lys Thr Lys Gly Ser Gly Phe Phe-Y¹

Lys Thr Lys Gly Ser Gly Phe Phe Val Phe-Y¹

Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe-Y¹

Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe-Y¹

Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe-Y¹

wherein ^y1 is hydroxyl, -NH₂ or methoxy.

[0019] The peptides of this invention may be prepared by methods known in the art of peptide synthesis comprising the sequential coupling of the amino acids from which the peptide is derived.

[0020] Methods of sequential coupling of amino acids to form peptides by forming amide links are well known in the art. In general the amino acids, provided with protecting groups where necessary, are coupled in the correct order, or smaller peptides are combined into larger units. The amide linkage is usually prepared by condensing an amino acid, or peptide, having a protected a-amino group and a free or activated terminal carboxyl group, with an amino acid or peptide with a protected carboxyl group and a free a-amino group.

[0021] Activation of the carboxyl group can be effected, for example, by converting the carboxyl group into an acid halide, an azide, anhydride or imidazolide, or into an activated ester such as the cyanomethyl ester, p-nitrophenyl ester, 2,4,5-trichlorophenyl ester, pentachlorophenyl ester, N-hydroxysuccinimide ester or benztriazole ester.

[0022] The most widely used methods of condensation of amino acids or peptides include the carbodiimide method, the azide method, the anhydride method, and the activated esters method, as described, for example, by Schroder and Lubke in "The Peptides", Volume 1 (1969), (Academic Press). An alternative method is the solid phase method of Merrifield (J. Am. Chem. Soc., 85, 2149 (1963)).

[0023] Any reactive groups in the amino acid or peptide which are not to take part in the condensation reaction should be protected by any of the N-protecting groups or carboxyl protecting groups described above which can be readily removed after the condensation.

[0024] The removal of the protecting group(s) present in the resultant peptide may be effected by an appropriate procedure depending upon the kind(s) of the protective group(s). Some typical procedures are as follows: hydrogenation in the presence of palladium catalyst (e.g. palladium carbon, palladium black) for benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-bromo-benzyloxycarbonyl, p-phenylazobenzyloxycarbonyl, p-(p'-methoxyphenylazo)-benzyloxycarbonyl and trityl groups protecting the amino end; treatment with hydrogen bromide in glacial acetic acid for benzyloxycarbonyl, p-bromobenzyloxycarbonyl, p-phenylazobenzyloxycarbonyl and t-butyloxycarbonyl groups protecting the amino end; treatment with metallic sodium in liquid ammonia for benzyloxycarbonyl, p-bromobenzyloxycarbonyl and tosyl groups protecting the amino end; treatment with hydrochloric acid and/or acetic acid for trityl, t-butyloxycarbonyl, formyl and benzylidene groups protecting the amino end; treatment with alkali for methyl, ethyl and benzyl esters protecting the carboxyl end; treatment with acid for methyl, ethyl, benzyl, p-methoxybenzyl and t-butyl esters protecting the carboxyl end; and hydrogenation in the presence of palladium catalyst for benzyl and p-nitrobenzyl esters protecting the carboxyl end.

[0025] Acid addition salts of compounds of formula (I) are included within this invention, for example the salts of pharmaceutically acceptable acids as a hydrohalide, especially the hydrochloride or hydrobromide; or the phosphate, acetate, phenylpropionate, maleate, tartrate and citrate.

[0026] The peptides and salts of the present invention may be employed as the active agents in desensitisation vaccines. Such vaccines are well known to those skilled in the art and comprise a sterile liquid vehicle in which the active agent is dissolved or suspended. If suspended, the particles of active agent should be small enough not to block the orifice of an injection needle. Certain adjuvants such as tyrosine are often included in such vaccine compositions and are believed to provide a support and prolonged slow release of active material in vivo. Usually a patient receiving treatment with such desensitisation vaccines is administered a number of injections, spread over a period of weeks or days, each injection containing a higher concentration of active agent than the preceding one. In this way the patient is desensitised such that his allergic reaction to allergens is reduced or eliminated.

[0027] An alternative mode of administration for desensitisation agents is by application to the nasal mucosa as a liquid spray or as a dry powder snuff.

[0028] Yet another possible route of administration would be by application to the buccal mucosa, again as a liquid or dry composition.

[0029] Accordingly, the present invention includes a pharmaceutical composition for use in desensitisation therapy, comprising a peptide or pharmaceutically acceptable salt of formula (I) together with a pharmaceutically acceptable carrier suitable for parenteral, intra-nasal or buccal administration.

[0030] The compositions of the invention may be administered in conventional manner for desensitisation therapy.

[0031] The invention also provides a peptide of the formula (I) as defined, or a salt thereof, for use in the desensitisation therapy of allergies.

[0032] The preparation and properties of some of the peptides of this invention are illustrated by the following examples.

[0033] Peptides were synthesized by classical methods of peptide synthesis described in the literature of peptide chemistry, for example by means of classical solution synthesis or solid phase peptide synthesis (SPPS), or by use of a combination of these methods.

[0034] Where appropriate amino acids refer to the L-configuration unless otherwise stated, and the following abbreviations are used:

Example 1

The preparation of LysThrLysGIySerGIyPhePheOMe

[0035] The octapeptide methyl ester was prepared by a 4 + 4 fragment condensation strategy, one fragment (I) being prepared by solid phase peptide synthesis (SPPS) (according to SPPS Manual by J. M. Stewart and J. D. Young Freeman and Company, San Francisco, 1969) and the other fragment (11) by classical solution synthesis. Combination of I and II gave fully protected octapeptide (III) which on deprotection afforded the desired product (V).

(I) BOC Lys(Z)Thr(Bzl)Lys(Z)Gly N₂H₃

[0036] This intermediate was prepared by SPPS, employing standard DCCI mediated coupling procedures using a 0.47 mM/g glycine substituted Merrifield Resin. The fully protected tetrapeptide- resin was cleaved by treatment with 100 equivalents of hydrazine hydrate in DMF at room temperature for 3 days. Standard work-up gave I in good yield. This was crystallised from EtOH/water and then EtAc; m.p. 132-134°C; TLC homogeneous in 9:1 CHCl₃:MeOH/l₂ stain with Rf 0.44; NMR consistent with structure;

(C = 1, DMF); amino acid analysis:

(II) Ser(Bzl)GlyPhePheOMe.HCI

[0037] The tetrapeptide methyl ester hydrochloride was prepared by solution synthesis in six stages.

(i) BOC-Phe.Phe.OMe:

[0038] BOC-Phe-OSu (5.25 g, 0.0145 M) was coupled to Phe.OMe. HCL (3.13 g, 0.0145 M) in DMF (25 ml) in the presence of 1 equivalent of Et₃N (2.03 ml) at room temperature over 3 days. The reaction mixture was poured into water (250 ml) and the product extracted into EtAc (100 ml). It was isolated in 8196 (5.00 g) yield and crystallisation from petrol (b.pt. 80-100°C) gave a m.p. of 123-124°C;

= -11.0° (C = 1, DMF).

(ii) Phe.Phe.Ome.HCl:

[0039] The intermediate (i) (4.65 g) was BOC-deprotected using a solution of 2N HCL in EtAc (30 ml) over 2 hours at room temperature. The product precipitated from solution in 78% yield (3.10 g) and had m.p. 205°C;

(C = 1, AcOH).

(iii) BOC.Gly.Phe.Phe.OMe:

[0040] BOC.Gly.OSu (2.18 g, 0.008 M) was coupled to (ii) (2.90 g, 0.008 M) in DMF in the presence of 1 equivalent of Et₃N (1.12 ml) at room temperature over 3 days. Similar work-up described for isolation of (i), gave the product in 67% yield (2.60 g); m.p. 159-161 °C, after crystallisation from EtAc (40 ml)

(C = 1, DMF); amino acid analysis:

(iv) GIyPhePheOMe.HCl:

[0041] The intermediate (iii) (2.60 g) was BOC-deprotected in a similar manner to that described for (ii). The product deposited as an oil which was triturated with ether to give a white crystalline solid in almost quantitative yield. The material was purified further on Sephadex LH20 column eluting with water and had m.p. 196-199°C; TLC in 9:1 CHCI₃:MeOH showed one spot with 1₂ stain at Rf. 0.22. Amino acid analvsis:

(v) BOC.Ser(Bzl)GIyPhePheOMe:

[0042] BOC.Ser(Bzl)OH (1.66 g, 0.0056 M) was coupled to (iv) (2.36 g, 0.0056 M) in MDC (20 ml) at 0°C using DCCI (1.16 g, 0.0056 M) and Et₃N (0.79 ml: 1 equivalent). The reaction mixture was stirred at 0°C for hour, room temperature for 2 hours, filtered and filtrate evaporated in vacuo. Crystallisation of the residue from EtAc/petrol (80-100°C) afforded a 67% yield (2.50 g) of product, m.p.. 163-167°C. TLC in 9:1 CHCI₃:MeOH (1₂ stain) showed product at Rf 0.68;

(C = 1, DMF). The NMR spectrum was consistent with structure. Amino acid analysis:

(vi) Ser(BzI)GlyPhePheOMe.HCI (II):

[0043] Intermediate (v) (1.75 g) above was BOC-deprotected in a similar manner to that described for (ii). Addition of ether to the reaction mixture gave the product as a solid in 96% yield (1.52 g),

21.0° (C = 1, AcOH). It was purified on Sephadex LH20 eluting with 1 M AcOH,

(C = 1, AcOH) TLC examination in 9:1 CHCI₃:MeOH (1₂ stain) showed product (acetate salt) as one spot at Rf 0.27. The NMR spectrum was consistent with structure. Amino acid analysis:

(III) BOC.Lys(Z)Thr(Bzl)Lys(Z)GlySer(Bzl)GlyPhePheOMe

[0044] Tertiary-butyl nitrite (0.32 ml, 0.00266 M) was added with vigorous stirring to a solution of (I) (1.60 g, 0.00177 M) in DMF (30 ml) containing 60 equivalents 2N HCL in THF (5.5 ml, 0.0011 M) at -20°C. After 30 minutes, (II) (1.05 g, 0.00177 M) in DMF (5 ml) with sufficient Et₃N (2.11 ml) present to neutralise all HCI present, was added, and the reaction mixture stirred for 18 hours at 4°C, filtered and filtrate concentrated in vacuo. Addition of cold water gave the product which was obtained in 50% yield (1.28 g) after crystallisation from EtOH. TLC in 9:1 CHCI₃:MeOH (1₂ stain) was homogeneous and showed product at Rf 0.6. M.p. 202-203°C;

(C = 1, DMF). The NMR spectrum was consistent with structure. Amino acid analysis:

(IV) Lys(Z)Thr(BzI)Lys(Z)Glyser(BzI)GlyPhePheome.HCI

[0045] Fully protected octapeptide (III) (1.20 g) was BOC-deprotected in 2N HCI solution in a 6:14 DMF/EtAc solvent mixture (20 mI). Prolonged reaction time of 4 hours was used at room temperature and addition of ether deposited the product. Recrystallisation from MeOH/ether gave a 52% yield (0.60 g) of product. TLC in 9:1 CHCl₃:MeOH (I₂ stain) showed one major spot at Rf 0.4;

(C = 1, AcOH) Amino acid analysis:

(V) LysThrLysGlySerGlyPhePheOMe

[0046] Partially protected octapeptide (IV) (0.10 g) was hydrogenated in 85% AcOH (70 ml) with 10% Pd/C catalyst (0.20 g) over a steady stream of hydrogen for 20 hours. The mixture was filtered, evaporated in vacuo and residue filtered on Sephadex LH20 eluting with water to give the desired octapeptide methyl ester (V) (0.03 g, 46% yield). TLC examination showed 1 spot at Rf 0.2 in 5:2:2 BAW (t-BuOCI/KI-starch stain) and Rf 0.5 in 5:2:3 BAW (Ninhydrin stain). Amino acid analysis:

Isotachophoretic examination showed one band in >95% amount (leading electrolyte 10 mM KOH + MES pH 6.0 and terminating electrolyte 10 mM β-alanine and HCI pH 4.23). The NMR 80 MHz FT spectrum was consistent with structure.

Example 2

The preparation of ArgLysThrLysGlySerGlyPhePheOMe

[0047] This nonapeptide was prepared by coupling of (IV) above with Z.Arg(Z)₂.OSu, followed by hydrogenolysis of the resultant fully protected nonapeptide.

[0048] (i) Z.Arg(Z),Lys(Z)Thr(Bzl)Lys(Z)GlySer(Bzl)GlyPhePheOMe:

To octapeptide (IV) (0.344 g, 0.30025 M) above in DMF (3 ml) at 0°C was added (1 equivalent) Et₃N (0.025 g in 1 ml DMF) and Z-Arg(Z)₂OSu (0.17 g, 0.00025 M in 2 ml DMF). The solution was left at 4°C for 65 hours, diluted with water (8 ml) and the deposited product filtered off and dried (0.37 g, 78% yield). Crystallisation from DMF/EtOH gave product with m.p. 204-210°C (decomposition). TLC examination in 9:1 CHCI₃:MeOH (1₂ stain) showed on U.V. visualisation 1 spot at Rf 0.69. The NMR spectrum was consistent with structure. Amino acid analysis:

(ii) ArgLysThrLysGlySerGlyPhePheOMe

[0049] Fully protected nonapeptide (i) (0.07 g) above was dissolved in a minimum amount of DMF and 5 times the volume of AcOH added. The mixture was hydrogenated in the presence of 10% Pd/C catalyst (2.5 times weight of compound) for 19 hours at room temperature using a steady stream of hydrogen. Water was added to give a 15% aqueous solution and the mixture hydrogenated for a further 3 hours. Filtration and evaporation in vacuo at 45°C gave product as a glassy solid. Purification was performed on a Sephadex LH20 column eluting with 1 M AcOH and product isolated in 26% yield (0.018 g). TLC in 5:3:5 BAW (ninhydrin stain) showed product at Rf 0.34. Amino acid analysis:

Example 3

The preparation of LysThrLysGIySerGIyPhePheVaIPheOMe

[0050] The decapeptide methyl ester was synthesised by a 4 + 2 + 4 fragment condensation strategy as follows:-

(VI) BOC.Ser(BzI)Gly.OSu Prepared in three stages:-

(i) BOC.Ser(BzI)GIyOMe

[0051] BOC.Ser(Bzl)OH (5.0 g, 0.017 M) was coupled to Gly.OMe.HCI (2.13 g, 0.017 M) in M.D.C. (100 ml) at R.T. for 3½ hours in the presence of 1 equivalent of Et₃N and using DCCI (3.5 g, 0.017 M) as the condensing agent. The precipitate was filtered off and the solution washed X 2 with water, aqueous NaHC0₃, water, dried and evaporated in vacuo to leave an oil (7.1 g).

[0052] TLC 9:1 CHCI₃:MeOH (I₂ stain) showed one spot at Rf 0.64;

(C = 1, MeOH).

(ii) BOC.Ser(Bzl)GlyOH

[0053] Compound (i) above (7.0 g) was dissolved in dioxan (25 ml) and treated with an equal volume of 1N NaOH (25 ml) and the solution stirred for ½ hour at R.T. N HCI (25 ml) was added to a slight excess and the oil that formed extracted into EtAc. The organic layer was back-extracted into NaHC0₃ and acidified to pH 3.8 with 20% citric acid, extracted with EtAc, the organic layer washed with water, brine, dried and evaporated to leave the product as a syrup (4.0 g).

[0054] TLC 1:1 CHCl₃/EtOH (I₂ stain) showed product at Rf 0.59. The NMR spectrum was consistent with structure.

(iii) BOC.Ser(Bzl)GlyOSu

[0055] Compound (ii) above (4 g, 0.01135 M) was treated with HOSu (1.3 g, 0.011 M) and DCCI (2.34 g, 0.011 M) in dioxan (50 ml) at R.T. overnight. The precipitate that formed was filtered off, solvent removed and the product crystallised from I.P.A. (100 ml) in 59% yield (3.00 g). TLC 9:1 CHCl₃/MeOH (I₂ stain) showed one major spot Rf 0.57; M.P. 132-134°C;

(C = 1, MeOH).

(VII) PhePheValPheOMe Prepared in six steps:-

(i) BOC.ValPheOMe

[0056] BOC.VaIOSu (10.0 g, 0.0328 M) was coupled to PheOMe.HCI (6.85 g 0.0318 M) in toluene (2.00 ml) at room temperature overnight and in the presence of Et₃N (1 equivalent). The mixture was filtered and filtrate washed with 1N HCI, saturated NaCl solution, dried and evaporated in vacuo to give the product (11.31 g) as a white crystalline compound in 94% yield.

[0057] TLC in 9:1 (CHCI₃:MeOH) (1₂ stain) shows one spot at Rf 0.77

(C = 1, MeOH).

(ii) ValPheOMe.HCl

[0058] Compound (i) (9.25 g) was BOC-deprotected in 2N HCI in EtAc (100 ml) for 24 hours at room temperature when the product precipitated. The mix was diluted with dry EtAc and product filtered off in 78% yield (6.0 g). The product was finally purified on Sephadex LH20. M.P. 193-193.5°.

[0059] TLC 9:1 CHCl₃/MeOH (1₂ stain) shows one spot at Rf 0.60.

(C = 1, AcOH).

(iii) BOC.PheValPheOMe

[0060] Compound (ii) (5.34 g, 0.017 M) was coupled to BOC.PheOSu (6.15 g, 0.017 M) in 25% DMF in toluene (250 ml) at room temperature for 65 hours in the presence of Et₃N (1 equiv.). The mixture was then filtered, solvent removed in vacuo and the syrup quenched with water. The white precipitate (8.5 g) was filtered off and recrystallised from EtAc/80-100⁰ petrol; yield 80%.

[0061] TLC 9:1 CHCl₃/MeOH (I₂ stain) shows one spot at Rf 0.69

(C = 1, MeOH). NMR consistent with structure.

(iv) PheValPheOMe.HCI

[0062] Compound (iii) (6.87 g) was BOC-deprotected in 2N HCI in EtAc (100 ml) for 2 hours at room temperature when a white solid precipitate (5.84 g) representing 97% yield of product. M.P. 243-245° (decomposition).

[0063] TLC 9:1 CHCl₃/MeOH (I₂ stain) shows one spot at Rf 0.59.

(C = 1, AcOH).

(v) BOC.PhePheValPheOMe

[0064] BOC.PheOSu (4.30 g, 0.0119 M) was coupled to compound (iv) (5.5 g, 0.0119 M) in toluene (100 ml) at room temperature for 65 hours in the presence of sufficient DMF to produce solution, and also in the presence of Et₃N (1 equivalent). The solvent was evaporated in vacuo and the syrup quenched with water and product filtered off. The product was then triturated with hot ethanol, cooled and collected (6.38 g, 80% yield). M.P. 218-219°C.

[0065] TLC in 9:1 CHCI₃:MeOH (1₂ stain) shows one spot at Rf 0.62.

(C = 1, DMF). The NMR spectrum was consistent with structure.

(vi) PhePheValPheOMe.Tfa

[0066] Compound (v) (5 g) was BOC-deprotected in T.F.A. (25 ml) at 0°C for ½ hour, and at room temperature for

hour. The solution was then quenched with ether (75 ml) and the product filtered off (4.48 g, 88% yield). M.P. 224-226° (decomposition).

[0067] TLC 9:1 CHCI₃:MeOH (1₂ stain) shows one spot at Rf 0.49.

(C = 1, AcOH). The NMR spectrum was consistent with structure.

(VIII) Ser(Bzl)GlyPhePheVaIPhe.OMe Prepared in two stages:-

(i) BOC.Ser(Bzl)GlyPhePheValPheOMe

[0068] Intermediate VI (2.37 g, 0.00528 M) was coupled to intermediate VII (3.62 g, 0.00528 M) in toluene (500 ml) overnight at room temperature in the presence of Et₃N (0.74 ml, 0.00528 M). The mixture was washed with water, and solvent evaporated in vacuo. The solid obtained was triturated with water, dried and recrystallized from EtOH (4.42 g, yield 93%).

[0069] TLC 9:1 CHCl₃:MeOH (1₂ stain) shows one spot at Rf 0.61.

(C = 1 DMF). The NMR spectrum was consistent with structure.

(ii) Ser(Bzl)GlyPhePheValPheOMe

[0070] Compound (i) (2.8 g) was BOC-deprotected in T.F.A. (30 ml) for 40 minutes at 0°C. The solution was quenched with ether (200 ml) and the precipitated product obtained in quantitative yield.

[0071] TLC 9:1 CHCI₃:MeOH (1₂ stain) shows one spot at Rf 0.2. M.P. 214-216°C (decomposition).

3.7° (C = 1, AcOH). The NMR spectrum was consistent with structure.

BOC.Lys(Z)Thr(Bzl)Lyq(Z)GlySer(Bzl)GlyPhePheValPheOMe

[0072] Peptide I (2.25 g) (see Example 1) was coupled to VIII (2.19 g) by the Honzl-Rudinger modification of the azide method, as previously described for the octapeptide. The product was recrystallized from EtOH and obtained in (2.5 g, 61% yield). M.P. 243-244°.



(C = 1, DMF). The NMR spectrum was consistent with structure.

LysThrLysGlySerGlyPhePheValPheOMe

[0073] The intermediate above (0.18 g) was BOC, Z and Bzl-deprotected by treatment with 33% HBr in dioxan (5 ml) at room temperature for 1 hour when a precipitate formed. Additional HBr/dioxan (5 ml) and water (1 ml) was then added which effected solution and reaction continued for a further 1 2 hour. Acetone (50 ml) was then added and the solution quenched with ether (100 ml). The supernatent was decanted and solid dissolved in water (7 ml) and freeze-dried to give 0.145 g product as the tri- hydrobromide salt.

An aliquot of product was purified on Sephadex LH20 eluting with water, to a one-spot material with Rf 0.384 (BAW 5:2:2, ninhydrin spray).

Example 4

[0074] The preparation of LysThrLysGIySerGIyPhePheVal.PheOH The decapeptide free acid was synthesised by a 4 + 2 + 4 fragment condensation strategy as follows:-

(IX) PhePheValPheOBz Prepared in six stages:

(i) BOC.ValPheOBz

[0075] BOC.VaIOSu (15.7 g, 0.050 M) was coupled to PheOBz.pTsa (21.35 g, 0.050 M) in dioxan (200 ml) at R.T. for 41 2 hours in the presence of 1 equivalent of Et₃N. The reaction mixture was evaporated at reduced pressure and the resulting residue dissolved in EtAc and the solution washed with water, dried and evaporated in vacuo to leave a crystalline solid (21.3 g).

[0076] TLC 9:1 CHCI₃:MeOH (I₂ stain) showed one spot at Rf 0.93. [α]^25°_D = -31.8° (C = 1, MeOH).

(ii) VaIPheOBz.HCI

[0077] Compound (i) (21.3 g) was BOC-deprotected in 2N HCI in EtAc (240 ml) for 41 2 hours at R.T. when the product precipitated. The mix was diluted with dry ether and product filtered off in 78% yield (15.25 g). M.P. 180-182°.

[0078] TLC 9:1 CHCI₃:MeOH (I₂ stain) shows one spot at Rf 0.44. [α]^25°_D = 24.4° (C = 1, AcOH).

(iii) BOC.PheValPheOBz

[0079] Compound (ii) (15.25 g, 0.039 M) was coupled to BOC.PheOSu (14.13 g, 0.039 M) in 50% dioxan/DMF (450 ml) at R.T. for 4 hours in the presence of Et₃N (1 equivalent). The mixture was poured into iced water and the resulting white precipitate (20.0 g) was filtered off and recrystallised from EtAc/40-60° petrol; yield 85%. M.P. 160-162°.

[0080] TLC 9:1 CHCI₃:MeOH (I₂ stain) shows one spot at Rf 0.72. [α]²⁵_D= -36.0° (C = 1, MeOH).

(iv) Phe VaIPheOBzHCl

[0081] Compound (iii) (20.0 g, 0.033M) was BOC-deprotected in 2N HCI in EtAc (240ml) for 2 hours at R.T. when a white solid precipitated (15.23 g) representing 85% yield of product. M.P. 228-229° (decomposition).

[0082] TLC 9:1 CHCI₃:MeOH (I₂ stain) shows one spot at Rf 0.63. [α]^25°_D = -6.9° (C = 1, AcOH).

(v) BOC.PhePheValPheOBz

[0083] BOC.PheOSu (10.26 g, 0.0283 M) was coupled to compound (iv) (15.23 g, 0.0283 M) in 50% dioxan/DMF (250 ml) at R.T. for 4 hours in the presence of Et₃N (1 equivalent). The mixture was poured into iced water and the resulting white precipitate filtered off and recrystallised from EtAc/40-60⁰ petrol in quantitative yield (21.41 g). M.P. 191-193°.

[0084] TLC 9:1 CHCI₃:MeOH (I₂ stain) shows one spot at Rf 0.72. [α]^25°_D= -12.8° (C = 1, DMF).

(vi) PhePheValPheOBzHCI

[0085] Compound (v) (21.15 g, 0.028 M) was BOC-deprotected in 2N HCI in EtAc (500 ML) for 2 hours at R.T. The product (17.9 g) was precipitated in 92% yield upon addition of dry ether. M.P. 242° (decomposition).

[0086] TLC 9:1 CHCI₃:MeOH (I₂ stain) shows one spot at Rf 0.74. [α]^25°_D = -5.9° (C = 1, AcOH). The NMR spectrum was consistent with structure.

(X) Ser(BzI)GlyPhePheValPheOBz Prepared in two stages:-

(i) BOC.Ser(BzI)GlyPhePheValPheOBz

[0087] Intermediate (VI) (4.49 g, 0.010 M) was coupled to intermediate (IX) (6.85 g, 0.010 M) in 35% DMF/dioxan (75 ml) at R.T. for 4 hours in the presence of Et₃N (1 equivalent). The mixture was poured into iced water and the precipitated product (9.39 g) recrystallised from methanol in 91% yield. M.P. 226-228°.

[0088] TLC 9:1 CHCI₃:MeOH (1₂ stain) shows one spot at Rf 0.74. [α]^25°_D =-13.0° (C = 1, DMF). The F.T. 'H NMR was consistent with structure.

(ii) Ser(Bzl)GlyPhePheValPheOBzHCl

[0089] Compound (i) (5.0 g, 0.0051 M) was BOC-deprotected in 2N HCI in EtAc (150 ml) for 2 hours at R.T. The product (4.42 g) was precipitated in 94% yield upon addition of dry ether. M.P. 232-234° (decomposition).

[0090] TLC 9:1 CHCI₃:MeOH (1₂ stain) shows one spot at Rf 0.44. [α]²⁵°_D=-4.3° (C = 1, AcOH). The NMR was consistent with structure.

(XI) ZLys(Z)Thr(Bzl)Lys(Z)GlyOTcp Prepared in seven stages:-

(i) BOC.Lys(Z)GIyOMe

[0091] BOC.Lys(Z)OSu (23.85 g, 0.050 M) was coupled to GlyOMe. HCI (6.25 g, 0.050 M) in 50% dioxan/DMF at R.T. for 1 2 hours in the presence of 1 equivalent of Et₃N. The reaction mixture was evaporated in vacuo and the residue dissolved in EtAc. The solution was washed, dried, filtered and evaporated to a colourless oil which solidified on standing in 89% yield.

[0092] TLC 9:1 CHCl₃:MeOH (1₂ stain) showed one spot at Rf 0.54.

(ii) Lys(Z)GlyOMe.HCl

[0093] Compound (i) (20.00 g, 0.0443 M) was BOC-deprotected in 2N HCI in EtAc (250 ml) for 2 hours at R.T. when the product precipitated. The mixture was diluted with dry ether and the product filtered off in 96% yield (15.67 g). M.P. 158-159°.

[0094] TLC EtAc (1₂ stain) showed one spot at Rf 0.52.

(iii) BOC.Thr(Bzl)Lys(Z)GlyOMe

[0095] BOC.Thr(Bzl)OH (6.18 g, 0.020 M) was coupled to compound (ii) (7.76 g, 0.020 M) in 30% DMF/dioxan (75 ml) in iced water for 1 hour then at R.T. for a further 2 hours in the presence of DCCI (1 equivalent) and Et₃N (1 equivalent). The reaction mixture was filtered and evaporated in vacuo and the residue purified by silica column chromatography eluting with chloroform. The product was isolated as a colourless solid in 49% yield. M.P. 135-136°.

[0096] TLC 9:1 CHCI₃:MeOH (I₂ stain) showed one spot at Rf 0.57. The F.T. ¹³C NMR was consistent with structure.

(iv) Thr(Bzl)Lys(Z)GlyOMe.HCl

[0097] Compound (iii) (3.48 g, 0.0054 M) was BOC-deprotected in 2N HCI in EtAc (100 ml) for 2 hours at R.T. The product (2.88 g) was precipitated in 91 % yield upon addition of dry ether. M.P. 100-101 °. TLC 9:1 CHCI₃:MeOH (1₂ stain) showed one spot at Rf 0.52. [α]^25°_D -13.5° (C = 1, AcOH).

(v) ZLys(Z)Thr(Bzl)Lys(Z)GlyOMe

[0098] ZLys (Z)OTcp (1.80 g, 0.003 M) was coupled to compound (iv) (1.72 g, 0.003 M) in dioxan (45 ml) at R.T. for 4 hours in the presence of Et₃N (1 equivalent). The product was filtered off, washed with water and dried in vacuo (1.36 g, 50% yield). M.P. 185-188°.

[0099] TLC 9:1 CHCI₃:MeOH (I₂ stain) showed one spot at Rf 0.76.

(vi) ZLys(Z)Thr(Bzl)Lys(Z)GlyOH

[0100] A solution of compound (v) (0.92 g, 0.001 M) in 50% DMF/methanol was treated with 1N NaOH solution (2.5 ml) and stirred at R.T. for 1 hour. Upon acidification the precipitated product (0.45 g) was recrystallised from methanol in 49% yield. M.P. 171-173°.

[0101] TLC 2:1 CHCl₃:MeOH (t.butyl chloroformate/Nal - starch spray) showed one spot at Rf 0.50. [α]²⁵°_D = -5.4° (C = 1, AcOH). The F.T. ¹³C NMR was consistent with structure.

(vii) ZLys(Z)Thr(Bzl)Lys(Z)GlyOTcp

[0102] A solution of TcpOH (0.10 g, 0.0005 M) and compound (vi) (0.46 g, 0.0005 M) in DMF was treated with DCCI (0.11 g, 0.0005 M) and stirred at 5° for 1 hour then at R.T. overnight. The reaction mixture was filtered and the product (0.60 g) isolated as a crispy solid upon evaporation in vacuo. M.P. 176-178°.

[0103] TLC 9:1 CHCI₃:MeOH (I₂ stain) showed one spot at Rf 0.71. [α]²⁵°_D = -6.0° (C = 1, AcOH).

ZL ys(Z)Thr(Bzl)Lys(Z)GlySer(Bzl)GlyPhePheValPheOBz

[0104] Peptide (XI) (0.55 g, 0.0005 M) was coupled to compound (X) (0.46 g, 0.0005 M) in DMF at R.T. for 4 hours in the presence of Et₃N (1 equivalent). The reaction mixture was poured into iced water and the resulting precipitate filtered off and dried in vacuo. Purification by silica column chromatography, eluting with CHCI₃, gave the product (0.92 g) in 85% yield.

[0105] TLC 9:1 CHCl₃:MeOH (1₂ stain) showed one spot at Rf 0.34. The F.T. ¹³C NMR was consistent with structure.

LysThrLysGlySerGlyPhePheValPheOH

[0106] The intermediate above (0.76 g, 0.0003 M) was deprotected by continuous hydrogenation in 85% acetic acid with 1N HCI (1 mM) for 18 hours in the presence of 10% Pd/charcoal (0.80 g). The product was purified on a Biogel P2 column eluting with 1 M ammonium acetate and subsequently on a CM32 cellulose column eluting with 0.1 M ammonium acetate pH5. Final isolation of the product in 23% yield was by lyopholisation.

[0107] TLC butanol/acetic acid/water (5:2:2) (ninhydrin spray) showed one spot at Rf 0.22. Amino acid analysis:

[0108] 

Example 5

The preparation of ProArgLysThrLysGlySerGlyPhePheOMe

[0109] This decapeptide was synthesised by a 1 + 1 + 4 + 4 fragment condensation strategy as follows:-

(XII) Lys(Z)Thr(Bzl)Lys(Z)GlyOMe Prepared in two steps from Thr(Bzl)Lys(Z)GlyOMe described in example 4.

(i) BOC.Lys(Z)Thr(Bzl)Lys(Z)GlyOMe

[0110] BOC.Lys(Z)OSu (2.38 g, 0.005 M) was coupled to Thr(Bzl)Lys(Z)GlyOMe.HCl (2.87 g, 0.005 M) in dioxan (60 ml) at R.T. for 4 hours in the presence of Et₃N (1 equivalent). The reaction mixture was poured into iced water to give the required product (3.80 g) as a crystalline white solid in 84% yield. M.P. 103-105°.

[0111] TLC 9:1 CHCI₃:MeOH (I₂ stain) showed one spot at Rf 0.55. [α]²⁵°_D= -10.4° (C = 1, AcOH).

(ii) Lys(Z)Thr(Bzl)Lys(Z)GlyOMe.HCl

[0112] Compound (i) (3.80 g, 0.0042 M) was BOC-deprotected in 2N HCI in EtAc (100 ml) for 2 hours at R.T. The product (3.30 g) was precipitated in 93% yield upon addition of dry ether. M.P. 184-186°. TLC 9:1 CHCI₃:MeOH (I₂ stain) showed one spot at Rf 0.30. [α]²⁵°_D = 5.6° (C = 1, AcOH).

(XIII) Arg(NO₂)Lys(Z)Thr(Bzl)Lys(Z)GlyOMe Prepared in two stages:-

(i) BOC.Arg(NO₂)Lys(Z)Thr(Bzl)Lys(Z)GlyOMe

[0113] BOC.Arg(NO₂)OSu (1.40 g, 0.0033 M) was coupled to compound (XII) (3.30 g, 0.004 M) in 10% DMF/dioxan (55 ml) at R.T. for 3 hours in the presence of Et₃N (1 equivalent). Unreacted (XII) was filtered off and the reaction mixture poured into iced water, extracted with EtAc to give the product (2.60 g) which was recrystallised from IPA in 71% yield. M.P. 133-135°.

[0114] TLC 9:1 CHCI₃:MeOH (1₂ stain) showed one spot at Rf 0.42. [α]^25°_D = -6.7° (C = 1, AcOH).

(ii) Arg(NO₂)Lys(Z)Thr(Bzl)Lys(Z)GlyOMe.HCl

[0115] Compound (i) (2.0 g, 0.0018 M) was BOC-deprotected in 2N HCI in EtAc (50 ml) for 2 hours at R.T. The product (1.75 g) was precipitated in 92% yield upon addition of dry ether. M.P. 157° (decomposition).

[0116] TLC 2:1 CHCI₃:MeOH (1₂ stain) showed one spot at Rf 0.53. [α]^25°_D = -5.6° (C = 1, MeOH).

(XIV) ZProArg(NO₂)Lys(Z)Thr(Bzl)Lys(Z)GlyOH Prepared in two stages:-

(i) ZProArg(NO₂)Lys(Z)Thr(Bzl)Lys(Z)GlyOMe

[0117] ZProOSu (0.57 g, 0.0016 M) was coupled to compound (XIII) (1.71 g, 0.0016 M) in 20% DMF/dioxan (30 ml) at R.T. for 2 hours in the presence of Et₃N (1 equivalent). The reaction mixture was poured into iced water and extracted with EtAc to give the product (1.11 g) in 54% yields.

[0118] TLC 9:1 CHCl₃:MeOH (1₂ stain) showed one spot at Rf 0.36.

(ii) ZProArg(NO₂)Lys(Z)Thr(Bzl)Lys(Z)GlyOH

[0119] A solution of compound (i) (0.87 g, 0.0007 M) in 50% DMF/methanol (30 ml) was treated with 1 N NaOH solution (1.7 ml) and stirred at R.T. for 2 hours. Acidification precipitated the product (0.43 g) in 50% yield.

[0120] TLC 2:1 CHCl₃:MeOH (1₂ stain) showed one spot at Rf 0.77. [α]^25°_D = -4.1 ° (C = 1, AcOH). The NMR was consistent with structure.

ZProArg(NO₂)Lys(Z)Thr(Bzl)Lys(Z)GlySer(Bzl)GlyPhePheOMe

[0121] Peptide (XIV) (0.40 g, 0.0033 M) was coupled to compound (II) (0.20 g, 0.0034 M) in DMF (5 ml) in the presence of Et₃N (1 equivalent), DCCI (0.07 g, 0.0035 M) and hydroxybenzotriazole (0.044 g, 0.0035 M) at 5° for 1 hour then at R.T. for 1 hour. The precipitated urea was filtered off and the required product (0.50 g) isolated by pouring the reaction mixture into iced water and isolating by filtration in 88% yield.

[0122] TLC 9:1 CHCI₃:MeOH (1₂ stain) showed one spot at Rf 0.52. The NMR was consistent with structure.

ProArgLysThrLysGlySerGlyPhePheOMe

[0123] The intermediate above (0.40 g, 0.0022 M) was deprotected by continuous hydrogenation in 85% acetic acid for 18 hours in the presence of 10% Pd/charcoal catalyst (0.40 g). The product was purified on a Biogel P2 column eluting with water and subsequently on an LH20 Sephadex column again with aqueous elution. Final isolation of the product in 34% yield was by lyopholisation.

[0124] TLC BAW (5:2:2) (ninhydrin spray) showed one spot at Rf 0.34. Amino acid analysis:

[0125] 

Example 6

The preparation of LysThrLysGlySerGlyPhePheOH

[0126] The octapeptide free acid was synthesized by a 4 + 4 fragment condensation strategy as follows:

(XV) Ser(Bzl)GlyPhePheOBz Prepared in six stages:-

(i) BOCPhePheOBz

[0127] BOCPheOH (11.88 g, 0.045 M) was coupled to PheOBz.pTsa 19.4 g, 0.045 M) in MDC (200 ml) at 0° for 1 hour then at R.T. overnight in the presence of Et₃N (1 equivalent) and DCCI (1 equivalent). The reaction mixture was filtered and the product (14.92 g) isolated in 64% yield upon evaporation in vacuo and recrystallisation from EtOAc/80-100° petrol (14.92 g). M.P. 123.5-124.5°.

[0128] TLC 1:1 EtAC: 80-100° petrol (1₂ stain) showed one spot at Rf 0.68. [α]^25°_D = -16.7° (C = 1, MeOH).

(ii) PhePheOBz.Tfa

[0129] Compound (i) (14.0 g, 0.028 M) was BOC-deprotected in 50% TFA in MDC (100 ml) for 1 2 hour at 0°. The solution was quenched with dry ether and the product (14.23 g) filtered off in quantitative yield. M.P. 180° (decomposition).

[0130] TLC 9:1 CHCI₃:MeOH (1₂ stain) showed one spot at Rf 0.73. [α]^25°_D = 17.5° (C = 1, AcOH).

(iii) BOCGlyPhePheOBz

[0131] BOC.GlyOSu (9.6 g, 0.0353 M) was coupled to compound (ii) (18.20 g, 0.0353 M) in toluene, MDC and DMF (125 ml) at R.T. overnight in the presence of Et₃N (1 equivalent). The reaction mixture was evaporated at reduced pressure and the resulting residue dissolved in EtAc, washed, dried and evaporated in vacuo to leave a crystalline solid (19.71 g) in quantitative yield. M.P. 127-130°.

[0132] TLC 9:1 CHCI₃:MeOH (1₂ stain) showed one spot at Rf 0.81. [α]^25°_D = -17.4° (C = 1, MeOH).

(iv) GlyPhePheOBz.Tfa

[0133] Compound (iii) (19.3 g, 0.0346 M) was BOC-deprotected in 50% TFA in MDC (130 ml) for 11 2 hours at 0°. The solution was quenched with ether and the product (17.79 g) filtered off in 90% yield. TLC 9:1 CHCI₃:MeOH (1₂ stain) showed a single spot at Rf 0.35. [α]^25°_D = 6.0° (C = 1, AcOH).

(v) BOC.Ser(Bzl)GlyPhePheOBz

[0134] BOC.Ser(Bzl)OSu (11.03 g, 0.0282 M) was coupled to compound (iv) (16.13 g, 0.0282 M) in 15% DMF/toluene (350 ml) at R.T. overnight in the presence of Et₃N (1 equivalent). The reaction mixture was evaporated at reduced pressure and the resulting residue dissolved in EtAc, washed, dried and evaporated in vacuo to give the product (14.88 g) in 72% yield upon recrystallisation from EtAc/petrol. M.P. 149-151°.

[0135] TLC 9:1 CHCI₃:MeOH (I₂ stain) showed a single spot at Rf 0.65. [α]^25°_D = -11.2° (C = 1, MeOH).

(vi) Ser(Bzl)GlyPhePheOBz

[0136] Compound (v) (14.45 g, 0.0196 M) was BOC-deprotected in 50% TFA in MDC (140 ml) for 1 hour at 0°. The solution was quenched with ether and the product (13.1 g) filtered off in 89% yield. M.P. 185-187° (decomposition).

[0137] TLC 9:1 CHCI₃:MeOH (I₂ stain) showed one spot at Rf 0.43. [α]^25°_D = 10.1 ° (C = 1, AcOH).

[0138] (XVI) BOC.Lys(Z)Thr(Bzl)Lys(Z)GlyOSu Prepared in four stages from BOC.Thr(Bzl)Lys(Z)GlyOMe described in example 4.

(i) Thr(Bzl)Lys(Z)GlyOMe.Tfa

[0139] BOC.Thr(Bzl)Lys(Z)GlyOMe (2.87 g, 0.0045 M) was BOC-deprotected in 50% TFA in MDC (50 ml) for 1 hour at 0°. The solution was quenched with ether and the product (2.10 g) filtered off in 72% yield.

[0140] TLC 9:1 CHCl₃:MeOH (I₂ stain) showed one spot at Rf 0.26.

(ii) BOC.Lys(Z)Thr(Bzl)Lys(Z)GlyOMe

[0141] BOC.Lys(Z)OSu (2.00 g, 0.003 M) was coupled to compound (i) (1.45 g, 0.003 M) in 10% DMF/toluene at R.T. overnight. The reaction mixture was evaporated at reduced pressure and the resulting residue dissolved in EtAc, washed, dried and evaporated in vacuo to give the product (2.04 g) in 74% yield upon recrystallisation from EtAc/petrol. M.P. 117-119°.

[0142] TLC 9:1 CHCl₃:Me0H (I₂ stain) showed one spot at Rf 0.60.

(iii) BOC.Lys(Z)Thr(Bzl)Lys(Z)GlyOH

[0143] A solution of compound (ii) (1.98 g, 0.0022 M) in DMSO (30 ml) was treated with 1N NaOH solution (11 2 equivalents) and stirred at R.T. for 1 hour. Acidification gave the product (1.82 g) in quantitative yield.

[0144] TLC 5:1 CHCl₃:MeOH (I₂ stain) showed compound just above baseline.

(iv) BOC.Lys(Z)Thr(Bzl)Lys(Z)GlyOSu

[0145] HOSu (0.24 g, 0.002 M) was coupled to compound (iii) (1.82 g, 0.002 M) in dioxan (25 ml) at R.T. for 4 hours in the presence of DCCI (1 equivalent). The reaction mixture was filtered and the filtrate evaporated at reduced pressure. Recrystallisation of the residue from EtOH gave the product (0.30 g) in _15% yield. M.P. 118-¹²²°.

[0146] TLC 9:1 CHCI₃:MeOH (1₂ stain) showed one spot at Rf 0.50. [α]^25°_D = -4.0° (C = 1, DMF). The NMR was consistent with structure.

BOC.Lys(Z)Thr(Bzl)Lys(Z)GlySer(Bzl)GlyPhePheOBz

[0147] Peptide (XVI) (0.22 g, 0.0023 M) was coupled to compound (XV) (0.17 g, 0.0023 M) in 5% DMF/toluene (21 ml) at R.T. overnight in the presence of Et₃N (1 equivalent). The reaction mixture was evaporated at reduced pressure and the residue recrystallised from EtOH to give the product (0.29 g) in 85% yield. M.P. 195-199°.

[0148] TLC 9:1 CHCI₃:MeOH (I₂ stain) showed one spot at Rf 0.67. The NMR was consistent with structure.

LysThrLysGlySerGlyPhePheOH

[0149] The intermediate above (0.25 g, 0.0017 M) was dissolved in TFA (10 ml) and deprotected by bubbling through HBr at R.T. for 1 hour. The solution was quenched with dry ether and the product dried in vacuo over P₂0, and KOH. The product was purified on a Biogel P2 column eluting with water and subsequently on a CM32 cellulose column eluting with a linear ionic strength gradient of ammonium acetate pH5 which gave separation of the free acid and some benzyl ester contaminant. Final isolation of the product was by lyopholisation.

[0150] TLC BAW (5:2:2) (ninhydrin spray) showed one spot at Rf 0.20. Amino acid analysis:

[0151] 

Biological Activity

[0152] Biological results obtained for Examples 1-6 in three different assay systems are presented in Tables 1 and 2.

[0153] As is apparent from Table 1, the peptides were capable of releasing histamine selectively from rat mast cells in vitro, and producing histamine release effects in rat and baboon skin in vivo. In the latter case in particular (primate tissue) activity was unusually high.

[0154] Table 2 demonstrates cross-desensitisation in rat mast cells in vitro between the peptides of Example 3 and an antigen.

[0155] 

Methods

[0156] (a) (1) Histamine, (2) Cr51 and (3) Lactic Dehydrogenase Release from Rat Peritoneal Mast Cells (Rat Mast Cell in vitro test)

[0157] Mast cells, derived from the peritoneal washings of three male, outbred Wistar rates (250-300 g), were purified by the procedure according to Cooper and Stanworth (Preparative Biochem. 4(2), 105, 1975).

[0158] The purified cells were washed twice in Dulbecco's incomplete (i.e. free from mineral salts) buffer and then resuspended in Dulbecco's medium to the required volume. In a typical experiment, sufficient cells were available for 30 duplicate challenges, i.e. 60 samples and in this case the resuspension volume employed was 6.1 mls. 0.1 ml of cell suspension were taken for estimating the cell count.

(1) Histamine release:

[0159] One third of the cell suspension was employed. To 0.9 ml duplicate aliquots of challenge solution, prepared in complete Dulbecco's medium and prewarmed to 37°C, was added 0.1 ml of cell suspensions. The solutions were then shaken gently, and allowed to incubate for 5 minutes at 37°C. The reaction tubes were then quickly removed from the incubator and placed in an ice bath. Supernatants were then separated from the cell population following centrifugation for 3 minutes at 1000 r.p.m. The cell residues were then treated with 2 mls of 0.4 N perchloric acid and allowed to stand for approximately 30 minutes at ambient centrifugation and the supernatant solutions set aside for histamine analysis. The original supernatant solutions were treated with 1.0 ml of 0.8 N perchlorate and then treated in a similar manner to the cell residues. Histamine was measured by the method according to Evans, Lewis and Thompson (Life Sciences, 12, 327, 1973) using a Technicon Auto- analyser^*. Histamine release was calculated as a percentage of total histamine available in each challenge solution.

(2) Cr⁵¹ release:

[0160] One third of the cell suspension was employed. To approximately 2.0 ml of cell suspension in Dulbecco's medium was added 0.1 ml of a solution of Cr⁵¹ labelled sodium chromate. Approximately 50-100 µCi Cr⁵¹ was employed (specific activity: 300-500 µCi/mg Cr). The cells were allowed to stand for 30 minutes at ambient temperature and then excess chromium was removed by washing the cells three times in Dulbecco's buffer. The cell pellet was finally resuspended in the same buffer and 0.1 ml of cell suspension was then added to 0.9 ml of each challenge solution, prewarmed to 37°C. After 5 minutes' incubation the cell suspensions were removed from the water bath and the supernatants separated by centrifugation. Activity present in the whole recovered supernatants was measured using a Tracer Laboratory Spectromatic y counter. The percentage of Cr⁵¹ released was assessed in relation to the values obtained for the positive and negative control solutions.

(3) LDH measurement:

[0161] One third of the cell suspension was employed. The incubation procedure was identical to that described above and carried out simultaneously until the challenge solution supernatants were separated from the cell residues. Lactic dehydrogenase activity was then estimated directly in the supernatant solutions by the method according to Johnson and Erdos (Proc. Soc. Exp. Biol. Med. 142. 1252. 1973). To 0.5 ml of supernatant was added 0.5 ml of NAD (1 mM in 0.2 M Tris buffer, pH 8.5). 0.5 ml of this solution was then taken and treated with 50 ,ul of lactic acid (50 mM in 0.2 M Tris buffer, pH 8.5); as control, 50 ,ul of 0.2 M Tris buffer (pH 8.5) was added to a second aliquot (0.5 ml) of the NAD solution. The solutions were incubated at ambient temperature for 20 minutes and the fluorescence emission was then measured. The excitation and emission wave lengths used were 340 and 460 nm respectively. All measurements were carried out using a Baird Atomic automatic spectro- fluorimeter (Fluoripoint). The LDH activity was assessed in terms of the increase of fluorescence over control due to NADH formation following lactate addition. The percentage of LDH released was assessed in relation to the fluorescence intensity obtained in the positive control challenge solution supernatants (i.e. Triton X 100 challenge).

(b) Skin Test Method

[0162] Skin tests were carried out in the shaved backs of animals (rats and baboons) immediately after intravenous injection of pontamine sky blue (5%) in aqueous sodium chloride solution (0.9%) at a dose of 0.1 ml per kilogram of body weight in the base of rats and 5 ml per animal in the case of baboons.

[0163] Peptide in aqueous sodium chloride solution (0.9%), or saline control, were injected intradermally in 0.05 ml or 0.10 ml volumes. Skin reactions were read 20 minutes after intradermal challenge.

[0164] • (Technicon is a Registered Trade Mark, at least in the United Kingdom)

[0165] (c) Cross Desensitisation in the vitro rat mast cell system between antigen and peptide

[0166] Brown Norway rats were immunised intraperitoneally with 100 µg of ovalbumen (XOA) in 1 mg 'alum'. On day 27, peritoneal mast cells were removed, bulked and washed. Aliquots of cells were desensitised by the addition of 4 x 5 minute incubations with various peptide concentrations or buffer alone. The cells were then submitted to an optimal histamine releasing challenge of peptide, XOA, or challenged with buffer alone.

Claims

1. A peptide, or a salt thereof, characterised by containing 6 to 12 naturally occuring amino acid residues in a sequence wherein,

R₁ consists of a residue of a basic amino acid, optionally linked to one or more residue of a neutral non-hydrophobic amino acid and/or to one or more further residue of a basic amino acid;

R₂ consists of one or more residue of a neutral non-hydrophobic amino acid; and

R₃ consists of a residue of a hydrophobic amino acid, optionally linked to one or more residue of a neutral non-hydrophobic amino acid and/or to one or more further residue of a hydrophobic amino acid;

the said basic amino acid residues are selected from arginyl, lysyl and ornithyl;

the said neutral non-hydrophobic amino acid residues are selected from glycyl, alanyl, seryl and threonyl; and

the said hydrophobic amino acid residues are selected from phenylalanyl, valyl and leucyl said peptide having the formula (I):

wherein the sequence⁅R₁-R₂-R₃⁆ is as defined and;

X is hydrogen, or a N-protecting group;

Y is hydroxy, or a C-terminal protecting group; and

R is an optionally present group, capable of confering on a peptide resistance to enzyme breakdown.

2. A peptide according to claim 1, wherein R is not present, X is hydrogen and Y is hydroxy, amino or methoxy.

3. A peptide according to claim 1 or claim 2, wherein the⁅R₁-R₂-R₃⁆ sequence has from 8 to 10 amino acid residues.

4. A peptide according to claim 1, 2 or 3, wherein R₃ only contains hydrophobic amino acid residues.

5. A peptide according to claim 1 having the structure

wherein X, Y and R are as defined in claim 1; c and e are lysyl, arginyl or ornithyl; d is threonyl or seryl; b is an optionally present arginyl, lysyl or ornithyl; f and h are glycyl or alanyl; g is seryl or threonyl; i and ji are phenylalanyl, valyl or leucyl; and k and I are optionally present phenylalanyl, valyl or leucyl; or a salt thereof.

6. A peptide according to claim 5, wherein X is hydrogen, Y is hydroxyl, amino, or methoxy, and R is not present.

7. A peptide as claimed in claim 1 selected from:

Lys Thr Lys Gly Ser Gly Phe Phe-Y¹

Arg Lys Thr Gly Ser Gly Phe Phe-Y¹

. Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe-Y¹

Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe-Y¹

Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe-Y¹

wherein Y¹ is hydroxyl, -NH, or methoxy, or a salt thereof.

8. Lys Thr Lys Gly Ser Gly Phe Phe Val PheOH, or a salt thereof.

9. Lys Thr Lys Gly Ser Gly Phe Phe Val Phe NH₂, or a salt thereof.

10. Lys Thr Lys Gly Ser Gly Phe Phe Val Phe OCH₃, or a salt thereof.

11. A pharmaceutical composition, for use in desensitisation therapy, comprising a peptide according to any one of the preceding claims or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, suitable for parenteral, intra-nasal or buccal administration.

12. A peptide, or a salt thereof, as defined in any one of the claims 1 to 10, for use in desensitisation therapy of allergies.

13. A process for the preparation of a peptide, or a salt thereof, as defined in any one of the claims 1 to 10, which process comprises the coupling of an optionally protected smaller peptide with either an optionally protected amino acid or with another optionally protected smaller peptide; and thereafter if desired removing any protecting group present, and if desired forming a salt of the peptide.

Revendications

1. Peptide ou sel de celui-ci, caractérisé en ce qu'il renferme de 6 à 12 restes d'amino-acide d'origine naturelle selon une séquence ⁅R₁-R₂-R₃⁆, dans laquelle:

R₁ est un résidu d'un amino-acide basique relié éventuellement à un ou plusieurs restes d'un amino-acide neutre non hydrophobe et/ou à un ou plusieurs autres restes d'un amino-acide basique;

R₂ est formé par un ou plusieurs restes d'un amino-acide neutre non hydrophobe; et

R₃ est un reste d'un amino-acide hydrophobe relié éventuellement à un ou plusieurs restes d'un amino-acide neutre non hydrophobe et/ou à un ou plusieurs autres restes d'un amino-acide hydrophobe;

les restes d'amino-acide basique sont choisis parmi l'arginyle, le lysyle et l'ornithyle;

les restes d'amino-acide neutre non hydrophobe sont choisis parmi le glycyle, l'alanyle, le séryle et le thréonyle; et

les restes d'amino-acide hydrophobe sont choisis parmi le phénylalanyle, le valyle et le leucyle;

ce peptide répondant à la formule (I):

dans laquelle la séquence ⁅R₁-R₂-R₃⁆ est telle que définie, et X est de l'hydrogène ou un groupe de protection à l'azote; Y est un hydroxy ou un groupe de protection du carbone terminal, et

R est un groupe éventuellement présent capable de conférer à un peptide une résistance à une dégradation par les enzymes.

2. Peptide suivant la revendication 1, caractérisé en ce que R n'est pas présent, X est de l'hydrogene et Y est un hydroxy, un amino ou un méthoxy.

3. Peptide suivant la revendication 1 ou 2, caractérisé en ce que la séquence ⁅R₁-R₂-R₃⁆ renferme de 8 à 10 restes d'amino-acide.

4. Peptide suivant la revendication 1, 2 ou 3, caractérisé en ce que R₃ contient simplement des restes d'amino-acide hydrophobe.

5. Peptide suivant la revendication 1, présentant la structure:

dans laquelle X, Y et R ont la même signification que dans la revendication 1; c et e sont du lysyle, de l'arginyle ou de l'ornithyle; d est du thréonyle ou du séryle; b est de l'arginyle, du lysyle ou de l'ornithyle éventuellement présent; f et h sont du glycyle ou de l'alanyle; g est du séryle ou du thréonyle; i et j sont du phénylalanyle, du valyle ou du leucyle; et k et I sont du phénylalanyle, du valyle ou du leucyle éventuellement présent; ou sel de ce peptide.

6. Peptide suivant la revendication 5, caractérisé en ce que X est de l'hydrogène, Y est un hydroxy, un amino ou un méthoxy et R n'est pas présent.

7. Peptide suivant la revendication 1, choisi parmi:

Lys Thr Lys Gly Ser Gly Phe Phe-Y'

Arg Lys Thr Lys Gly Ser Gly Phe Phe-Y'

Arg Lys Thr Lys Gly Ser Phe Phe Val Phe-Y'

Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe-Y¹

Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe-Y¹

où Y¹ est un hydroxy, -NH₂ ou méthoxy, ou sel de ce peptide.

8. Lys Thr Lys Gly Ser Gly Phe Phe Val Phe OH, ou sel de celui-ci.

9. Lys Thr Lys Gly Ser Gly Phe Phe Val Phe NH₂, ou sel de celui-ci.

10. Lys Thr Lys Gly Ser Gly Phe Phe Val Phe OCH₃, ou sel de celui-ci.

11. Composition pharmaceutique destinée à être utilisée en thérapeutique de désensibilisation, caractérisée en ce qu'elle renferme un peptide suivant l'une quelconque des revendications précédentes ou un sel pharmaceutiquement acceptable de celui-ci, conjointement à un véhicule ou excipient pharmaceutiquement acceptable convenant à une administration parentérale, intra-nasale ou buccale.

12. Peptide ou sel de celui-ci suivant l'une quelconque des revendications 1 à 10, destiné à être utilisé en thérapeutique de désensibilisation contre les allergies.

13. Procédé pour la préparation d'un peptide ou d'un sel de celui-ci suivant l'une quelconque des revendications 1 à 10, caractérisé en ce qu'il consiste à effectuer la condensation d'un peptide plus court éventuellement protégé avec soit un amino-acide éventuellement protégé, soit un autre peptide! plus court éventuellement protégé; puis si désiré à éliminir les groupes de protection présents et si désiré à former un sel du peptide.

Ansprüche

₁. Peptid oder dessen Salz, gekennzeichnet durch einen Gehalt an 6 bis 12 natürlich vorkommenden Aminosäuren in einer Folge ⁅R₁-R₂-R₃⁆, in der

R₁ aus einem Rest einer basischen Aminosäure besteht, die gegebenenfalls an einen oder mehrere Reste einer neutralen nicht-hydrophoben Aminosäure und/oder an einen oder mehrere Reste einer basischen Aminosäure gebunden ist,

R₂ aus einem oder mehreren Resten einer neutralen nicht-hydrophoben Aminosäure besteht und

R₃ aus einem Rest einer hydrophoben Aminosäure besteht, die gegebenenfalls an einen oder mehrere Reste einer neutralen nicht-hydrophoben Aminosäure und/oder an einen oder mehrere weitere Reste einer hydrophoben Aminosäure gebunden ist,

wobei die basischen Aminosäurereste aus des Gruppe Arginyl, Lysyl und Ornithyl ausgewählt sind und die neutralen nicht-hydrophoben Aminosäurereste aus der Gruppe Glycyl, Alanyl, Seryl und Threonyl ausgewählt sind und die hydrophoben Aminosäurereste aus der Gruppe Phenylalanyl, Valyl und Leucyl ausgewählt sind und

wobei das Peptid die Formel (I) hat:

in der die Folge ⁅R₁-R₂-R₃⁆ wie vorstehend definiert ist und

X ein Wasserstoffatom oder eine N-Schutzgruppe ist,

Y die Hydroxylgruppe oder eine Schutzgruppe für ein endständiges Kohlenstoffatom ist und

R eine gegebenenfalls vorliegende Gruppe ist, die einem Peptid Widerstandsfähigkeit gegen eine Enzymzersetzung verleihen kann.

2. Peptide nach Anspruch 1, wobei R nicht vorhanden ist, X ein Wasserstoffatom ist und Y die Hydroxyl-, Amino- oder Methoxygruppe ist.

3. Peptid nach Ansprüchen 1 oder 2, wobei die⁅R₁-R₂-R₃⁆-Folge 8 bis 10 Aminosäurereste hat.

4. Peptid nach den Ansprüchen 1, 2 oder 3, wobei R₃ nur hydrophobe-Aminosäurereste enthält.

5. Peptid nach Anspruch 1 mit der Struktur

in der X, Y und R wie in Anspruch 1 definiert sind, c und e Lysyl, Arginyl oder Ornithyl sind, d Threonyl oder Seryl ist, b gegebenenfalls vorhandenes Arginyl, Lysyl oder Ornithyl ist, f und h Glycyl oder Alanyl sind, g Seryl oder Threonyl ist, i und j Phenylalanyl, Valyl oder Leucyl sind, k und I gegebenenfalls vorhandenes Phenylalanyl, Valyl oder Leucyl sind, oder dessen Salz.

6. Peptid nach Anspruch 5, wobei X ein Wasserstoffatom ist, Y die Hydroxyl-, Amino- oder Methoxygruppe ist und R nicht vorhanden ist.

7. Peptid nach Anspruch 1, ausgewählt aus der Gruppe

Lys Thr Lys Gly Ser Gly Phe Phe-Y^l

Arg Lys Thr Lys Gly Ser Gly Phe Phe-Y^l

Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe-Y^l

Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe-Y¹

Prog Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe-Y^l

in der Y¹ die Hydroxyl-, -NH₂- oder Methoxygruppe oder ein Salz davon ist.

8. Lys Thr Lys Gly Ser Gly Phe Phe Val Phe OH oder dessen Salz.

9. Lys Thr Lys Gly Ser Gly Phe Phe Val Phe NH₂ oder dessen Salz.

10. Lys Thr Lys Gly Ser Gly Phe Phe Val Phe OCH₃ oder dessen Salz.

11. Pharmakologische Zubereitung zur Verwendung in der Desensitivierungstherapie, enthaltend ein Peptid nach einem der vorstehenden Ansprüche oder dessen pharmakologisch verträgliches Salz zusammen mit einem pharmakologisch verträglichen Trägermaterial für eine parenterale, intranasala oder bukkale Verabreichung.

12. Peptid oder dessen Salz nach einem der Ansprüche 1 bis 10 zur Verwendung in der Desensitivierungstherapie von Allergien.

13. Verfahren zur Herstellung eines Peptids oder dessen Salz nach einem der Ansprüche 1 bis 10, die Maßnahme der Kupplung eines gegebenenfalls geschützten kürzerkettigen Peptids mit entweder einer gegebenenfalls geschützten Aminosäure oder mit einem anderen gegebenenfalls geschützten kürzerkettigen Peptid und anschließend gegebenenfalls der Abspaltung vorhandener Schutzgruppe und gegebenenfalls der Bildung eines Salzes des Peptids umfassend.